key: cord-0755382-57edrxoh
authors: Abdelhafiz, Ahmed H.; Emmerton, Demelza; Sinclair, Alan J.
title: Diabetes in COVID‐19 pandemic‐prevalence, patient characteristics and adverse outcomes
date: 2021-03-14
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14112
sha: ef2b7eaa9a0741ec5efce95658c24d2cf4952e31
doc_id: 755382
cord_uid: 57edrxoh

BACKGROUND: Current literature on COVID‐19 pandemic has identified diabetes as a common comorbidity in patients affected. However, the evidence that diabetes increases the risk of infection, effect of diabetes on outcomes and characteristics of patients at risk is not clear. OBJECTIVES: To explore the prevalence of diabetes in COVID‐19 pandemic, effect of diabetes on clinical outcomes and to characterise the patients with diabetes affected by COVID‐19. METHODS: A literature review of articles published in English language and reported outcomes on prevalence and effect of diabetes on outcomes and patients’ characteristics. RESULTS: The prevalence of diabetes in COVID‐19 patients appears similar to that in the general population. The evidence of diabetes increasing the risk of severe infection and adverse outcomes is substantial. The progression of the disease into acute respiratory distress syndrome, the requirement for intensive care admission or mechanical ventilation and mortality all have been increased by the presence of diabetes. Patients with diabetes at risk of COVID‐19 appear to be obese, of older age, have uncontrolled glycaemia and have coexisting comorbidities especially cardiovascular disease and hypertension. Tight glycaemic control on admission to hospital using insulin infusion has shown some beneficial effects; however, the role of hypoglycaemic medications in the management of these patients is not yet clear. CONCLUSION: High risk group should be identified and prioritised in future vaccination programmes. Future research is required to optimise management of patients with diabetes and develop new ways to manage them via technological developments such as telecare.

In December 2019, a new coronavirus-the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) -has emerged in Wuhan, China and was named COVID-19 by the WHO. The virus spread rapidly across continents to cause a global pandemic. 1 Although the virus affected all age groups, the incidence was particularly shifted towards older age groups especially in those with underlying chronic health conditions. Among these chronic health conditions, diabetes mellitus in particular, appeared to be a major risk factor for both COVID-19 infection and worse outcomes. Diabetes is already known to be associated with increased mortality from any acute and chronic illness including infection. 2 

We undertook a detailed literature search with full assessment of relevant articles by searching the following databases: Google Scholar, Medline and Embase. We used Medical Subject Heading (MeSH) terms: diabetes mellitus, COVID-19, infection, comorbidity, patients' characteristics, risk factors, adverse outcomes, prevalence, mortality, predictors, disease progression, disease severity and glycaemic control. We searched articles for three categories of data:

1. Articles that reported diabetes as comorbidity in patients with COVID-19.

2. Articles that reported diabetes as a contributing factor to clinical outcomes.

3. Articles that specifically reported the characteristics of patients with diabetes affected by COVID-19.

Articles were reviewed for relevance by abstract. A manual search of citations in retrieved articles was performed in addition to the electronic literature search. We limited our selection to studies published in English language and reported clear outcomes. For data extractions, all articles derived from the search enquiry were independently examined by the authors, and data were extracted in a standardised format, which included study design, population studied and main findings.

Diabetes is commonly reported as a premorbid condition for people infected with COVID-19 although whether diabetes is a risk factor for this infection is still unclear. In a Chinese nationwide analysis of 1590 hospitalised patients with COVID-19, at least one comorbidity was present in 25.1% of patients. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 3 In a data analysis of 12 studies that included 2108 Chinese patients with confirmed SARS-Cov-2 infection, the prevalence of diabetes was 10.3%. 4 In another meta-analysis of six studies including 1527 Chinese patients, the proportions of hypertension, cardio-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. 5 and cancer (14.9%) being the most common. 9 The main international data reporting diabetes as a common comorbidity in patients with COVID-19 are summarised in Table 1 

A case series to describe the characteristics of 28 Chinese patients, mean (SD) age was 68.6 (9.0) years, 75% were males and 50% were admitted to Intensive care unit (ICU). The HbA1c level was similar between ICU (7.3%) and non-ICU (7.5%) patients but random blood glucose concentrations were significantly higher in ICU patients (13.7 mmol/L vs 9.8 mmol/L, P = .03 respectively). Seventeen (60.7%) patients had coexisting chronic diseases, including hypertension, heart disease, cerebrovascular disease and chronic respiratory disease. 12 In another study of 193 Chinese patients with severe COVID-19, 48 of them (24.9%) had diabetes. Compared with patients without diabetes, those with diabetes were older (70 years vs 60 years, P < .001), had more comorbidities (60.4% vs 44.8%, P = .06), were more likely to receive mechanical ventilation (81.3% vs 49.0%, P < .001) and had a higher mortality rate (81.3% vs 47.6%, P < .001). 13 In a Chinese study of 904 patients, 136 (15%) had diabetes, insulin usage was associated with poor prognosis while the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) was not associated with adverse clinical outcomes. 14 Data from the UK of a total of 3 154 300 patients with diabetes showed that uncontrolled diabetes (HbA1c > 86 mmol/mol vs 48-53 mmol/mol) and obesity (BMI > 40 kg/m 2 vs 25-29.9 kg/m 2 ) were independently associated with increased COVID-19 mortality in both type 1 and type 2 diabetes. 15 In the univariate analysis of the French study that included 1317 patients with diabetes hospitalised for COVID-19, characteristics significantly associated with the primary outcome (mechanical ventilation and/or death within 7 days of admission) were sex, BMI and previous treatment with renin angiotensin aldosterone system (RAAS) blockers, but not with age, type of diabetes, HbA1c, diabetic complications or glucose-lowering therapies. However, in multivariable analyses, only BMI remained positively associated with the primary outcome. 16 Data from the US showed that mortality rate was 28.8% in patients with diabetes or uncontrolled hyperglycaemia compared with only 6.2% for patients without diabetes or hyperglycaemia. Also, hyperglycaemia-related mortality was 41.7% compared with 14.8% for patients with diabetes but no hyperglycaemia suggesting that hyperglycaemia played a crucial role in adverse outcome. 17 Long duration of diabetes, uncontrolled glycaemia, obesity, increased prevalence of hypertension, chronic kidney disease and the common use of ACE inhibitors and ARBs were described in a British case series. 18 Characteristics of patients with diabetes and COVID-19 infection are summarised in Table 2 .

Diabetes was a common comorbidity in COVID-19 patients who were either admitted to ICU or died. [19] [20] [21] In a meta-analysis that included 1382 patients hospitalised for COVID-19, diabetes was identified as a risk factor for both ICU admission (OR 2.79, 95% CI 1.85-4.22, P < .0001) and mortality (3.21, 1.82-5.64, P < .0001). 22 In another meta-analysis of 1936 COVID-19 patients, diabetes significantly correlated with COVID-19 severity (OR 2.67, 95% CI 1.91-3.74, P < .01). 23 Prevalence of diabetes was also double in patients with COVID-19 who required ICU admission compared with those who did not. 24 Diabetes was the second most common morbidity in patients who reached a composite outcome of mechanical ventilation or death (26.9%) only second to hypertension (35.8%). 25 An outcome study has shown that in patients with COVID-19 who developed acute respiratory distress syndrome (ARDS), more patients had diabetes (19.0%) compared with those who did not (5.1%), respectively (difference, 13.9%, 95% CI 3.6%-24.2%). 26 It has also been reported that diabetes was the most common morbidity (22% in one study and 60% in another) of patients who died in hospital. 27, 28 Compared with patients with non-severe COVID-19, diabetes was more common in severe cases although it did not reach statistical significance (OR 2.07, 95% CI 0.89-4.82). 29 In a US retrospective chart review of all patients enrolled in a follow-up telemedicine outpatient clinic, the rate of hospitalisation for patients with diabetes was double (10.2%) the rate of hospitalisation for all other patients (5.1%), suggesting that the risk of severe COVID-19 is increased in individuals with diabetes. 30 Retrospective Chinese report has shown that compared with non-diabetes subjects, patients with diabetes were more likely to develop severe COVID-19 disease (P = .028) with more complications including acute respiratory distress (38.1% vs 19.5%, P = .001), acute cardiac injury (14.5% vs 5.1%, P = .016) and noninvasive and invasive mechanical ventilation (P = .037). 31 Diabetes as well as fasting blood glucose were independent risk factors for COVID-19 mortality (HR 3.641, 95% CI 1.086-12.214, P = .036 and 1.187, 1.078-1.306, P < .001, respectively) after adjustment for age, cardiovascular disease, chronic kidney disease and laboratory markers. 31 1.79-3.35, P < .001), ARDS (4.64, 1.86-11.58, P = .001) and disease progression (3.31, 1.08-10.14, P = .04). Meta-regression showed that the association with composite poor outcome was influenced by age (P = .003) and hypertension (P < .001). However, the presence of older age and hypertension attenuated the association of diabetes with the composite poor outcome. 33 In another systematic review that included case reports and case series studies has concluded that diabetes increases the risk of poor ARDS prognosis, severe symptoms of COVID-19 and mortality. 34 Main studies reporting outcomes of patients with diabetes and COVID-19 are summarised in Table 3 .

People with diabetes are at risk for greater susceptibility to COVID-19 infection and worse outcomes. This review aimed to explore the prevalence of diabetes in COVID-19 affected patients, whether it increases the risk of such infection, characteristics of patients at risk and their outcomes. (Figure 1 ).

Diabetes appears to be a common comorbidity in patients with Diabetes may increase the risk of infection because of immunologic defects, such as decreased neutrophilic migration, phagocytosis, intracellular killing and chemotaxis; however, the evidence remains controversial whether diabetes itself or the associated comorbidities is the main factor involved. 38

The most common characteristics of patients with diabetes who are affected by COVID-19 in addition to older age and multiple morbidities are uncontrolled glycaemia and obesity. [15] [16] [17] Diabetes and uncontrolled glycaemia have been previously reported as significant predictors of severity and mortality in patients with viral pneumonias. [39] [40] [41] Infection with COVID-19 in people with diabetes may increase stress that leads to increased secretion of hyperglycaemic hormones such as glucocorticoids and adrenaline thereby causing hyperglycaemia and fluctuating blood glucose levels. 42 The use of glucocorticoids in the treatment of severe COVID-19 may exacerbate the hyperglycaemia and the worse outcome observed could be as a result of the disease severity, manifested by hyperglycaemia, rather than hyperglycaemia per se. However, hyperglycaemia prior to the use of steroids was a determinant factor for short-term adverse outcomes. It has been shown that patients with admission glucose >11 mmol/L were more likely to develop ARDS (23.2% vs 9.2%), acute cardiac injury (12.5% vs 1.3%), to require ICU admission (21.4% vs 9.2%) and had a higher mortality ( Another study has also demonstrated that patients with impaired fasting glycaemia or diabetes had more composite end-point adverse events when compared with those with normal fasting glycaemia (18%, 31% and 5% respectively). 44 Poor glycaemic control before hospital admission has been shown to be associated with increased in-hospital mortality in a British cohort of 5500 patients with COVID-19. In a model analysis adjusted for sociodemographic factors and comorbidities has found that COVID-19 mortality is higher in patients with diabetes and HbA 1c > 86 mmol/mol (10%) compared with those with HbA 1c < 48 mmol/mol (6.5%). 45 Other studies have shown hyperglycaemia to be associated with worst chest radiographic findings, higher risk of composite adverse outcomes or mortality. [46] [47] [48] These findings suggest that hyperglycaemia, independent of glucocorticoid use, is a detrimental factor in adverse outcomes.

Also, the occurrence of hypoglycaemia because of variability of blood glucose levels may stimulate pro-inflammatory monocytes and increase platelet reactivity, contributing to a higher cardiovascular mortality in patients with diabetes. 49, 50 A recent study has shown that insulin infusion to tighten blood glucose control in patients with hyperglycaemia and hospitalised with COVID-19 has a protective effect. The study demonstrated that optimal glucose control in the immediate post-admission period for almost 18 days was associated with a significant reduction of inflammatory cytokines and pro-coagulant state which may reduce the risk of disease progression. 51 Globally, obesity has emerged as a significant risk factor for severe COVID-19 infection. [52] [53] [54] In a small study of 49 outpatients with diabetes and COVID-19, the reported median BMI was 33.9 with a range that reaches as high as 63.9 kg/m 2 . 30 Obesity is known to be associated with the severity and the longer duration 

The effect of diabetes mellitus, patient characteristics, common comorbidities and the potential therapeutic interventions on the outcome of COVID-19. CVD, cardiovascular disease; HTN, hypertension of viral infections. 55 Central obesity, which is the predominant type in individuals with diabetes, is particularly associated with higher risk resulting from the increased secretion of cytokines and chronic low-grade inflammation that may induce an impaired immune response. 56 Other factors may be related to the fact that obesity may reduce lung compliance, has maladaptive effects on ventilation and perfusion, mechanically impair ventilation with reduced aeration of the lung bases therefore leading to accumulation of secretions and increased risk of infection. 57-59

The evidence for the increased adverse outcomes of COVID-19 be- Diabetes may also be associated with decreased forced expiratory volume and forced vital capacity compromising optimal pulmonary function. 61 Diabetes-related complications may also be a factor.

Microangiopathic changes that occur in the respiratory tract may impair gas exchange and lung compliance, increasing susceptibility to lower respiratory tract infections by atypical microorganisms and severe pneumonias. 38 Other mechanisms may be related to the fact that the COVID-19 virus gains entry to pulmonary cells through binding to the membrane ACE2 receptor. The ACE inhibitors, ARBs and non-steroidal anti-inflammatory drugs that appear to increase ACE2 receptors expression, and therefore their use in people with diabetes may increase COVID-19 infectivity and illness severity. 62 On the contrary to this, these medications may reduce the pulmonary and systemic inflammatory response by decreasing cytokines and therefore may be beneficial. 63 Therefore, it is still unclear what is the balance between the benefits and the risks might be in continuing or stopping RAAS inhibitors. So far, no conclusive evidence exists to support the discontinuation of these agents in people with diabetes and COVID-19. 60 Other drugs used in the treatment of COVID-19 may have a deleterious effect on blood glucose level regulation such as the hyperglycaemic effect of glucocorticoids and the hypoglycaemic effect of hydroxychloroquine although this has not been clearly reported in the literature.

Frailty has not been formally assessed as a risk factor for COVID-19

infection in people with diabetes. However, because old age and multiple comorbidities are being associated with worse outcome in a proportional fashion, it is likely that frailty is a confounding unmeasured factor. 64 Diabetes is known to increase the risk of frailty. 65 Frailty is a syndrome that is characterised by multisystem, including immune system dysregulation which leads to reduced physiologic reserve and increased risk of adverse health outcomes including increased susceptibility to severe infections. Frailty has been shown to be associated with poor post-vaccination immune response, increased rates of influenza such as illness and laboratory-confirmed influenza infection. 66 In a prospective cohort study in a tertiary hospital investigating older 

The appropriate management of patients with diabetes and COVID-19

is not yet clear. Patients with diabetes should be declared as risk group for severe disease and worse outcomes. Future research may help develop a scoring system to identify vulnerable patients who may benefit from aggressive treatment or intensive support from outset to limit deterioration. Although a specific anti-viral drug is urgently required, a multi-target agent is also required to help regulate the dysregulated neuro-endocrine-immune system that is common in metabolic disease, including diabetes, cardiovascular disease, atherosclerosis, insulin resistance, hypertension, dyslipidaemia and obesity. The role of hypoglycaemic medications such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which may act as a receptor for COVID-19 and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), that may reduce inflammation, will need further investigation. 69 Therefore, future research is needed to provide a better understanding of the potential differences in genetic predispositions across populations and the underlying pathophysiological mechanisms. Finally, novel ways to deliver care to patients with diabetes using telehealth, remote patient monitoring and wearable technologies are required.

Diabetes appears to be a common morbidity in patients affected by COVID-19; however, the evidence that it increases the risk of infection is not yet clear. On the other hand, the evidence that diabetes increases the risk of severe disease and risk of adverse outcomes is substantial. Patients with diabetes who are at risk of COVID-19 tend to be obese, of older age, have uncontrolled diabetes and comorbidities, in particular cardiovascular disease and hypertension. Further research is still required to investigate appropriate management of people with diabetes and COVID-19 and develop novel ways of management including telecare.

The authors have declared no conflicts of interest.

Ahmed H. Abdelhafiz https://orcid.org/0000-0001-9098-6202

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest, et al. novel coronavirus outbreak in Wuhan, China

Mortality from infectious diseases in diabetes

Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Epidemiology of covid-19 in a long-term care facility in King County

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

Clinical characteristics of 28 patients with diabetes and COVID-19 in Wuhan

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication

Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a cohort study in people with diabetes. WWW.engla nd.nhs.uk/publi catio n/type-1-and-type-1diab etes-and-covid -19-relat ed-morta lity-in-england

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States

Characteristics of patients with diabetes hospitalised for COVID-19 infection-a brief case series report

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Epidemiology group of new coronavirus pneumonia emergency response mechanism of Chinese centre for disease control and prevention

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome

Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Clinical characteristics of coronavirus disease 2019 in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Characteristics and outcomes of COVID-19 positive patients with diabetes managed as outpatients

Comorbid diabetes mellitus was associated with poorer prognosis in patients with COVID-19: a retrospective cohort study

Factors associated with COVID-19-related death using OpenSAFELY

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression

Diabetes and COVID-19: a systematic review on the current evidences

Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013

England now have diabetes-Gov.uk. Accessed

Statistics about diabetes-American diabetes association

Diabetes and infection: is there a link? -a mini-review

Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS

Risk factors for severity and mortality in patients with MERS-CoV: analysis of publicly available data from Saudi Arabia

Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed

Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: a retrospective study

Impaired fasting glucose and diabetes are related to higher risks of complications and mortality among patients with coronavirus disease 2019

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study

Admission hyperglycemia and radiological findings of SARS-COV-2 in patients with and without diabetes

The clinical characteristics and outcomes of patients with diabetes mellitus and secondary hyperglycaemia with coronavirus disease 2019: a single-center, retrospective, observational study in Wuhan

Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19

Diabetes patients with COVID-19 need better care

Effect of hypoglycemia on inflammatory responses and the response to low-dose endotoxemia in humans

Outcomes in patients with hyperglycemia affected by Covid-19: can we do more on glycemic control? Diabetes Care

Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan detroit

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Impact of obesity on influenza a virus pathogenesis, immune response, and evolution

Obesity and the risk and outcome of infection

Obesity a risk factor for increased COVID19 prevalence, severity and lethality (Review)

Elevated levels of IL-6 and CRP predict the need for mechanical ventilElevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19ation in COVID-19

The effect of obesity on lung function

COVID-19 and diabetes: KNOWLEDGE in progress

Hispanics/Latinos with type 2 diabetes have functional and symptomatic pulmonary impairment Mirroring kidney microangiopathy: findings from the Hispanic community health Study/Study of Latinos (HCHS/SOL)

Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Age, frailty and diabetes -triple jeopardy for vulnerability to COVID-19 infection

Rodríguez-Mañas L. Frailty and sarcopenia -newly emerging and high impact complications of diabetes

Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults

Predictors of viral pneumonia: the need for viral testing in all patients hospitalized for nursing home-acquired pneumonia

The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications

Diabetes in COVID-19 pandemic-prevalence, patient characteristics and adverse outcomes